Literature DB >> 3142686

Effect of endoglycosidase F-peptidyl N-glycosidase F preparations on the surface components of the human erythrocyte.

M J Tanner1, D J Anstee, G Mallinson, K Ridgwell, P G Martin, N D Avent, S F Parsons.   

Abstract

Endo-N-acetyl-beta-D-glucosaminidase F-Peptidyl N-glycosidase F preparations (abbreviated Endo F) and endo-beta-D-galactosidase were used to study the major human erythrocyte membrane glycoproteins and the components carrying the blood group A, B, Rhesus (D), and Duffy (Fya) antigens. The results are consistent with the known presence of an N-glycosyl-linked oligosaccharide on sialoglycoprotein alpha and the absence of such an oligosaccharide from sialoglycoprotein delta. Under the conditions used, only a portion of the N-glycosyl-linked oligosaccharides on band 3 molecules were cleaved by Endo F alone or by Endo F in combination with endo-beta-D-galactosidase. Immunoblotting experiments showed that treatment of red cells with Endo F alone had little effect on the components carrying blood group A and B antigen activity. However, Endo F used in combination with endo-beta-D-galactosidase caused a substantial reduction in the binding of monoclonal anti-A and anti-B antibodies. The results clearly show that sialoglycoproteins alpha and delta carry little or no blood group A or B activity. Endo F alone, or in combination with endo-beta-D-galactosidase, had no effect on the electrophoretic mobility of the Rh(D) polypeptide, supporting previous suggestions that this membrane polypeptide is unusual in not being glycosylated. Endo F had a dramatic effect on the electrophoretic mobility of the component(s) carrying blood group Fya activity. The diffuse Fya component of Mr 38,500-90,000 was sharpened to a band of Mr 26,000. Either endo-beta-D-galactosidase or neuraminidase treatment reduced the Mr of the Fya component(s) but did not significantly sharpen the bands, suggesting that the Fya component contains between 40-50% by mass of N-glycosyl-linked oligosaccharides.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142686     DOI: 10.1016/0008-6215(88)80112-5

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  6 in total

1.  Rapid release of N-linked glycans from glycoproteins by pressure-cycling technology.

Authors:  Zoltan Szabo; András Guttman; Barry L Karger
Journal:  Anal Chem       Date:  2010-03-15       Impact factor: 6.986

2.  One-step immunopurification and lectinochemical characterization of the Duffy atypical chemokine receptor from human erythrocytes.

Authors:  Magdalena Grodecka; Olivier Bertrand; Ewa Karolak; Marek Lisowski; Kazimiera Waśniowska
Journal:  Glycoconj J       Date:  2012-01-14       Impact factor: 2.916

3.  Monoclonal antibodies to the membrane domain of the human erythrocyte anion transport protein. Localization of the C-terminus of the protein to the cytoplasmic side of the red cell membrane and distribution of the protein in some human tissues.

Authors:  S D Wainwright; M J Tanner; G E Martin; J E Yendle; C Holmes
Journal:  Biochem J       Date:  1989-02-15       Impact factor: 3.857

4.  New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.

Authors:  A Fletcher; J A Bryant; B Gardner; P A Judson; F A Spring; S F Parsons; G Mallinson; D J Anstee
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

5.  Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite.

Authors:  A Chaudhuri; J Polyakova; V Zbrzezna; K Williams; S Gulati; A O Pogo
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

6.  The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes.

Authors:  C E Chitnis; A Chaudhuri; R Horuk; A O Pogo; L H Miller
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.